Quantedge Capital’s Arcus Biosciences RCUS Stock Holding History

Quantedge Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-39,600	Closed	-$1M	–	264
2022 Q2	$1M	Buy	+39,600	New	+$970K	0.2%	125

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Quantedge Capital's RCUS Position: Q3 2022 in Review

Quantedge Capital sold out of Arcus Biosciences (RCUS) in Q3 2022, closing a stake of 39,600 shares — an estimated $1M sold.

Quantedge Capital first reported a position in RCUS in Q2 2022 and held it in 1 quarter. The position peaked at $1M in Q2 2022. 184 funds tracked by Wall St. Rank hold RCUS as of Q3 2022.

Quantedge Capital reported no remaining Arcus Biosciences position as of Q3 2022 after selling out during the quarter.
Quantedge Capital sold 39,600 Arcus Biosciences shares in Q3 2022, an estimated $1M.
Quantedge Capital first reported a position in Arcus Biosciences in Q2 2022 and held it in 1 quarter.
Quantedge Capital's Arcus Biosciences position peaked at $1M in Q2 2022.
184 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2022.

Based on Quantedge Capital's 13F filing for Q3 2022, filed 10 Nov 2022.